Investing carries serious risks, including partial or total loss of capital. Please read the Information Note and the Risk factors and login before investing.

Neutraceutical food patent company 1A

Tax Shelter
Equity Belgium 139 investors
Making industrial food cholesterol-friendly
Information Note Terms & Conditions
€1,000,000
Pre money valuation
33.3%
Equity offered
€209,000
Amount raised
€50,000
Committed by co-investors
4 days
Remaining
€50,000
Minimum target
418% funded

Guy Wyvekens

CEO

Guy WYVEKENS, a serial entrepreneur in various fields, each time followed by a resale (a communications agency for the pharmaceutical industry, aeronautics broker, medical device company).
In 2002, he founded the PHARCO laboratories specialised in food supplement.
In 2012, he sold their “ARTERIN” flagship product to the OMEGA PHARMA laboratories.
Three years later, the remainder of the product range was sold to the family holding of Marc Coucke - ALYCLO.
All this product range is still present on the Company of Marc Coucke “CERES PHARMA”
With his background on the pharmaceutical industry, he decided in 2016 to found a new laboratory “Normaphar” which is specialised in the treatment of metabolic disease such as cholesterol. They developed three ranges of products:
- Risk-free alternative for treating cholesterol - “Zeltrin” product
- Treatment of liver disease problems – “Lifasin” product
- Treatment of osteoporosis and osteopaenia – “Osteosin” product
The laboratory also developed a food patent at European level based on “specific extract of oyster mushrooms”. The company has decided to create a spin-off which will be in charge of the production and the marketing of this patented ingredient.

Bardet Anny

Marketing

Trilingual Marketing and Communication leader with extensive experience in business development, digital & direct marketing, external & internal coms, crisis com, reputation management, promotions, media & event management. Within reputable companies such as Unilever, Reckitt, Yves Rocher, JC Decaux, …

Strong track record in branding, increasing market share for established products and delivering strategic and operational marketing initiatives while managing a range of key stakeholders in B2B & B2C sectors.

TAX SHELTER 45%

This business qualifies for the startup tax shelter. If you meet the conditions, 45% of your investment will be reducted from your personal income taxes. Read more…
Please note €41,100 remains available for Tax Shelter investments.